Evidence map›Paper›PMID 42680835›Full record

ReviewNature reviews. Gastroenterology & hepatology2026

Long non-coding RNAs in colorectal cancer: shaping the tumour microenvironment and advancing precision oncology.

M Bartolini, F Battaglin, S Soni, S Algaze, K Ashouri, L Torres-Gonzalez, P Mittal, U Shah, W Zhang, J Millstein and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M BartoliniDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0004-6709-8265
F BattaglinDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
S SoniDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
S AlgazeDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
K AshouriDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
L Torres-GonzalezDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
P MittalDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
U ShahDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
W ZhangDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
J MillsteinDepartment of Population and Public Health Sciences, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
A PucciniDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
H-J LenzDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. lenz@med.usc.edu.ORCID http://orcid.org/0000-0003-2178-9568

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new frontier in cancer research is emerging with the exploration of 'dark DNA': the non-coding regions of the genome now recognized as essential regulators of cancer biology. Long non-coding RNAs (lncRNAs) have been increasingly acknowledged as key regulators in cancer, having crucial roles in the modulation of intracellular processes as well as in intercellular communication. These roles emphasize the importance of lncRNAs in influencing the tumour microenvironment (TME), a complex and dynamic network that contributes to cancer progression, metastasis and resistance to therapy. In this Review, we explore how lncRNAs regulate the colorectal cancer (CRC) microenvironment, focusing on their mechanisms of action and their effect on critical TME components, including immune cells, cancer-associated fibroblasts and angiogenesis. We explore the dual roles of lncRNAs as oncogenes or tumour suppressors, their involvement in immune modulation, vascular remodelling and extracellular matrix dynamics. Our comprehensive analysis elucidates the molecular pathways, identifies potential biomarkers for patient stratification and proposes new therapeutic strategies to regulate the CRC TME and prevent disease progression and resistance. Ultimately, this Review contributes to a deeper understanding of the intricate lncRNA-TME interplay and underscores their emerging relevance in clinical applications, paving the way for innovations in precision oncology.

Identifiers

PMID42680835

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.